webinar
Lipid formulations in softgels – enhancing bioavailability and therapeutic efficacy
27 June 2025 | By Thermo Fisher Scientific
This webinar will explore how lipid formulations in softgels can enhance drug absorption and bioavailability.
List view / Grid view
Drug Development
news
Radioligand therapy could address multiple cancer types
The investigational dual-targeting treatment provided strong and durable delivery to tumours, allowing for a high dose of targeted radiation, early results show.
article
Streamlining European expansion for cell and gene therapies
Tom Smith, Strategic Director, Cell and Gene Therapies, Uniphar, discusses the essential elements biotechs need for commercial success in Europe’s unique market when developing cell and gene therapies (CGTs).
news
iPSC-CAR-NK cell therapy exhibits autoimmune potential
The genetically edited allogeneic product could serve as an immune-modulatory therapy for severe autoimmune diseases, data suggests.
news
Life sciences a “priority sector” in UK Industrial Strategy
The new UK strategy represents a milestone for enhancing international competitiveness and puts into motion the upcoming Life Sciences Sector Plan.
news
NICE concludes decision for two Alzheimer’s treatments
The committee’s final draft guidance cited high-cost as a key reason for its negative opinion of the Alzheimer’s drugs, developed by Biogen and Eisai.
article
New biosimilar pathways – key takeaways from the EMA’s draft reflection paper
Here, Vladimir Murovec, Counsel, Osborne Clarke, discusses the European Medicines Agency (EMA)’s latest draft reflection paper and its scientific rationale, regulatory implications and potential impact on biosimilar drug development and manufacturing in the EU.
news
Eli Lilly genetic medicine acquisition to address cardiovascular risk
The agreement between Eli Lilly and Company and Verve Therapeutics could lead the way to single treatments that provide a long-term reduction of cardiovascular risk factors.
article
The rise of multimodal language models in drug development
Industry experts, Remco Jan Geukes Foppen, Vincenzo Gioia, Alessio Zoccoli and Carlos Velez reflect on the necessity to ensure data quality in order to gain full advantage from multimodal language models (MLMs).
news
Lancet study illustrates drug delivery “milestone”
The oral pill could address common drug adherence challenges in conditions such as schizophrenia, the clinical trial findings suggest.
news
FDA grants expanded approval for hepatitis drug
The FDA’s authorisation helps to address the “significant” remaining need for acute hepatitis C treatments, according to AbbVie.
news
Duchenne gene therapy interim trial outcomes “striking”
The gene therapy demonstrated consistent evidence of positively changing disease trajectory in Duchenne muscular dystrophy, new interim data shows.
news
European Council announces progress on pharmaceutical package adoption
The new EU rules for medicines aims to strengthen EU pharmaceutical competitiveness and reduce the regulatory burden.
news
BioNTech and BMS partner to advance oncology deal worth over $10 billion
The agreement involves an immunotherapy candidate with potential to innovate treatment of multiple tumour types, stated BMS.
news
R&D and tech innovation boosting biopharmaceutical market to 2030
Advanced technology innovation is driving lower R&D costs and progress of targeted treatments such as cell and gene therapies, the research reports.
